Avandia

On August 14, 2007 the U.S. Food and Drug Administration (FDA) announced that a number of diabetes drugs -- including Avandia (rosiglitazone) -- would now carry "black box" warnings on the risk of heart failure associated with use of the drugs. The "black box" warning is FDA's strongest form of warning. In July 2007 an FDA advisory committee recommended that Avandia remain on the market despite evidence that use of the drug increases the risk of heart attacks.

Click on the links below for information on Avandia (rosiglitazone) and related legal issues:

• Avandia Basics and Health Information
• Avandia - Recent News
• Avandia Links:
  • Long-term Risk of Cardiovascular Events With Avandia (Rosiglitazone) (Journal of the American Medical Association 9/12/07)
  • FDA Announcement on "Black Box" Warnings for Diabetes Drugs (8/14/2007)
  • FDA Safety Alert on Avandia (5/21/2007)
  • New England Journal of Medicine Study on Avandia
  • FDA Information on Avandia
• Defective & Dangerous Products - Legal Issues
• Defective & Dangerous Products - Get Help Now
• Defective & Dangerous Products A to Z

Page last updated on September 12, 2007